M W Kattan

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer
    Michael W Kattan
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Opin Urol 13:111-6. 2003
  2. ncbi Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 27, New York, NY 10021, USA
    J Clin Oncol 21:4568-71. 2003
  3. ncbi A competing-risks nomogram for sarcoma-specific death following local recurrence
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA
    Stat Med 22:3515-25. 2003
  4. ncbi Incorporating predictions of individual patient risk in clinical trials
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 22:348-52. 2004
  5. ncbi Comparison of Cox regression with other methods for determining prediction models and nomograms
    Michael W Kattan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Urol 170:S6-9; discussion S10. 2003
  6. ncbi Comparing treatment outcomes using utility assessment for health-related quality of life
    Michael W Kattan
    Departments of Urology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:1687-93; discussion 1693-4, 1697, 1701. 2003
  7. ncbi Evaluating a new marker's predictive contribution
    Michael W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Mailbox 27, New York, NY 10021, USA
    Clin Cancer Res 10:822-4. 2004
  8. ncbi Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Prostate Cancer 1:221-6. 2003
  9. ncbi Prediction of progression: nomograms of clinical utility
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Prostate Cancer 1:90-6. 2002
  10. ncbi Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
    M W Kattan
    Departments of Urology, Epidemiology and Biostatistics, and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3352-9. 2000

Collaborators

Detail Information

Publications126 found, 100 shown here

  1. ncbi Nomograms are superior to staging and risk grouping systems for identifying high-risk patients: preoperative application in prostate cancer
    Michael W Kattan
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Curr Opin Urol 13:111-6. 2003
    ..We discuss the goals of any staging system, what markers should be included, and models of markers...
  2. ncbi Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 27, New York, NY 10021, USA
    J Clin Oncol 21:4568-71. 2003
    ..The goal of this study was to create and to externally validate a nomogram for predicting the probability that a patient will develop metastasis within 5 years after three-dimensional conformal radiation therapy (CRT)...
  3. ncbi A competing-risks nomogram for sarcoma-specific death following local recurrence
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, USA
    Stat Med 22:3515-25. 2003
    ..A competing risks nomogram is produced to estimate the probability of death due to sarcoma for patients who have already developed a local recurrence of their initially treated soft-tissue sarcoma...
  4. ncbi Incorporating predictions of individual patient risk in clinical trials
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 22:348-52. 2004
    ..Clinical decisions could be informed by individualized estimates of treatment benefit, rather than by average treatment effects...
  5. ncbi Comparison of Cox regression with other methods for determining prediction models and nomograms
    Michael W Kattan
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Urol 170:S6-9; discussion S10. 2003
    ..There is controversy as to whether artificial neural networks and other machine learning methods provide predictions that are more accurate than those provided by traditional statistical models when applied to censored data...
  6. ncbi Comparing treatment outcomes using utility assessment for health-related quality of life
    Michael W Kattan
    Departments of Urology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Oncology (Williston Park) 17:1687-93; discussion 1693-4, 1697, 1701. 2003
    ..The popular approaches are described, and one particular method, the standard gamble, is advocated. Utility is easily measured by the standard gamble, and it has good psychometric and theoretical properties...
  7. ncbi Evaluating a new marker's predictive contribution
    Michael W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, Mailbox 27, New York, NY 10021, USA
    Clin Cancer Res 10:822-4. 2004
  8. ncbi Algorithms for prostate-specific antigen recurrence after treatment of localized prostate cancer
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Prostate Cancer 1:221-6. 2003
    ..We believe these tools are useful and necessary for patient counseling, follow-up scheduling, and clinical trial design and analysis...
  9. ncbi Prediction of progression: nomograms of clinical utility
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Clin Prostate Cancer 1:90-6. 2002
    ..Such an individualized approach should add value in medical decision making whenever an accurate prediction of the outcome may guide treatment selection...
  10. ncbi Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer
    M W Kattan
    Departments of Urology, Epidemiology and Biostatistics, and Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 18:3352-9. 2000
    ..The purpose of this study was to develop a nomogram to improve the accuracy of predicting outcome after three-dimensional conformal radiotherapy...
  11. ncbi Predicting clinical end points: treatment nomograms in prostate cancer
    Christopher J Di Blasio
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Semin Oncol 30:567-86. 2003
    ..There is need for additional models that predict other clinical end points, especially survival adjusted for quality of life...
  12. ncbi Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer
    Christopher J DiBlasio
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 62:9-18. 2003
    ..There is a need for additional nomograms that predict outcomes after salvage therapy, as well other clinical end points, including QOL-adjusted survival...
  13. ncbi A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer
    Ilias Cagiannos
    Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 170:1798-803. 2003
    ..CONCLUSIONS: Using clinical information, we produced 2 calibrated and validated nomograms, which accurately predict pathologically negative lymph nodes in men with localized prostate cancer who are candidates for radical prostatectomy...
  14. ncbi Body mass index is weakly associated with, and not a helpful predictor of, disease progression in men with clinically localized prostate carcinoma treated with radical prostatectomy
    Kozhaya N Mallah
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Cancer 103:2030-4. 2005
    ..These variables were of negligible prognostic value in men who received surgery. Studies with longer follow-up, that examine alternative end points, and that follow treatment(s) besides surgery are needed...
  15. ncbi Inventory of prostate cancer predictive tools
    Shahrokh F Shariat
    Department of Urology, University of Texas Southwestern Medical Centre, Dallas, Texas 75390 9110, USA
    Curr Opin Urol 18:279-96. 2008
    ..We describe the patient populations to which they apply and the outcomes predicted, and record their individual characteristics...
  16. ncbi Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Natl Cancer Inst 98:715-7. 2006
    ..Thus, a new preoperative nomogram provides robust predictions of prostate cancer recurrence up to 10 years after radical prostatectomy...
  17. ncbi Counseling men with prostate cancer: a nomogram for predicting the presence of small, moderately differentiated, confined tumors
    Michael W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 170:1792-7. 2003
    ..These nomograms have good discriminatory ability and calibration, and may benefit the patient and clinician when the various treatment options for prostate cancer are being considered...
  18. ncbi Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens
    Peter Swindle
    Department of Urology, Memorial Sloan Kettering Cancer Center, Sidney Kimmel Center for Prostate and Urologic Cancer, New York, New York 10021, USA
    J Urol 174:903-7. 2005
    ..We evaluated the prognostic significance of PSMs using multiple methods of analysis accounting for patients who received adjuvant therapy...
  19. ncbi Testosterone as a predictor of pathological stage in clinically localized prostate cancer
    Ginger Isom-Batz
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 173:1935-7. 2005
    ..4). CONCLUSIONS: On multivariate analysis low preoperative total testosterone was associated with advanced pathological stage but not with BCR. Future studies are warranted with data on more patients who have progressed...
  20. ncbi Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters
    Fernando J Bianco
    Departments of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 173:2099-103. 2005
    ....
  21. ncbi A postoperative prognostic nomogram for renal cell carcinoma
    M W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 166:63-7. 2001
    ..The nomogram may be useful for patient counseling, clinical trial design and patient followup planning...
  22. ncbi Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer
    M W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Urology 58:393-9. 2001
    ..CONCLUSIONS: The pretreatment nomogram we developed may be useful to physicians and patients in estimating the probability of successful treatment 5 years after brachytherapy for clinically localized prostate cancer...
  23. ncbi The definition of biochemical failure in patients treated with definitive radiotherapy
    M W Kattan
    Department of Biostatistics and Epidemiology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Int J Radiat Oncol Biol Phys 48:1469-74. 2000
    ..We have compared various modifications to the original ASTRO definition on our series of 1213 patients treated with transperineal permanent prostate brachytherapy...
  24. ncbi Customized dose prescription for permanent prostate brachytherapy: insights from a multicenter analysis of dosimetry outcomes
    Nelson N Stone
    Mount Sinai School of Medicine, New York, NY, USA
    Int J Radiat Oncol Biol Phys 69:1472-7. 2007
    ..To investigate the biochemical control rate in patients undergoing permanent prostate brachytherapy as a function of the biologically effective dose (BED) and risk group...
  25. ncbi Radical prostatectomy nomograms in black American men: accuracy and applicability
    Fernando J Bianco
    Department of Urology, Wayne State University, 4160 John R, Suite 1017, Detroit, MI 48201, USA
    J Urol 170:73-6; discussion 76-7. 2003
    ..78 and 0.74, respectively (p = 0.8). The postoperative index was 0.85 and 0.83, respectively (p = 0.9). CONCLUSIONS: Preoperative and postoperative nomograms can be applied accurately to an individual regardless of race...
  26. ncbi A tool for predicting breast carcinoma mortality in women who do not receive adjuvant therapy
    Michael W Kattan
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Cancer 101:2509-15. 2004
    ....
  27. ncbi Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer
    Michael Mullerad
    Departments of Urology and Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Urol 174:2158-63. 2005
    ..0001). CONCLUSIONS: For prostate cancer localization erMRI contributes significant incremental value to DRE or TRUS biopsy findings (each p <0.0001)...
  28. ncbi Importance of implant dosimetry for patients undergoing prostate brachytherapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, USA
    Urology 62:1073-7. 2003
    ..Overall, the reported 10-year BFR rates in this study were favorable. Strategies for ensuring the best quality implant should be used and, when reporting brachytherapy outcomes, the implant quality should be noted...
  29. ncbi Cancer control with radical prostatectomy alone in 1,000 consecutive patients
    Gerald W Hull
    Department of Urology, Medical University of South Carolina, Charleston, USA
    J Urol 167:528-34. 2002
    ..ml. Further research should address identifying patients who can safely avoid aggressive therapy...
  30. ncbi Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer
    Liang Wang
    Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, Rm. C-278, New York, NY 10021, USA
    AJR Am J Roentgenol 186:743-8. 2006
    ..01). CONCLUSION: Incorporation of the Partin nomogram results and MRI findings regarding both extracapsular extension and seminal vesicle invasion improves the MR prediction of LNM in patients with prostate cancer...
  31. ncbi Markers and meaning of primary treatment failure
    Peter W Swindle
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancer, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Urol Clin North Am 30:377-401. 2003
    ..Similarly, patients with a low risk of progression could be placed into observation protocols, potentially sparing them from exhaustive and inappropriate investigations...
  32. ncbi Preference assessment method affects decision-analytic recommendations: a prostate cancer treatment example
    Elena B Elkin
    Department of Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    Med Decis Making 24:504-10. 2004
    ..If decision analysis is used to counsel individual patients, careful consideration must be given to the method of preference elicitation...
  33. ncbi International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy
    Markus Graefen
    Department of Urology, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 20:3206-12. 2002
    ..Our results demonstrate that accurate predictions may be expected across different patient populations...
  34. ncbi Doctor, what are my chances of having a positive sentinel node? A validated nomogram for risk estimation
    José Luiz B Bevilacqua
    Department of Surgery, Memorial Sloan Kettering Cancer Center, MRI 1026, New York, NY 10021, USA
    J Clin Oncol 25:3670-9. 2007
    ..We developed a user-friendly prediction model (nomogram) based on a large data set to assist in predicting the presence of SLN metastasis...
  35. ncbi Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma
    Michael W Kattan
    Department of Urology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, C1275 New York, NY 10021, USA
    J Clin Oncol 21:3647-50. 2003
    ..This tool should be useful for patient counseling, follow-up scheduling, and clinical trial eligibility determination...
  36. ncbi Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy
    Thomas Steuber
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 120:1499-504. 2007
    ..0.715, p=0.039). In this setting, hK2 did not add diagnostic information. Measurements of individual forms of suPAR and PSA isoforms contributed significantly to discrimination of men with PCa from those with no evidence of malignancy...
  37. ncbi The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis
    Amita Shukla Dave
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 99:786-93. 2007
    ..To design new models that combine clinical variables and biopsy data with magnetic resonance imaging (MRI) and MR spectroscopic imaging (MRSI) data, and assess their value in predicting the probability of insignificant prostate cancer...
  38. ncbi Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors
    Cheryl T Lee
    Department of Urology, University of Michigan, 1500 E Medical Center Drive, Box 0330, Ann Arbor, MI 49109, USA
    Urol Oncol 21:179-84. 2003
    ..It may be reasonable to target RCC patients displaying altered bcl-2 levels for molecular therapies, such as anti-bcl2, should metastatic disease develop...
  39. ncbi Predicting nonsentinel node status after positive sentinel lymph biopsy for breast cancer: clinicians versus nomogram
    Michelle C Specht
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, New York 10021, USA
    Ann Surg Oncol 12:654-9. 2005
    ..It seems that most clinicians can improve their predictive ability by using the nomogram to predict the likelihood of additional non-SLN metastases in a woman with a positive SLN biopsy result...
  40. ncbi A catalog of prostate cancer nomograms
    P L Ross
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    J Urol 165:1562-8. 2001
    ..Selection among them and progress in this field are hampered by the lack of comparisons for predictive accuracy...
  41. ncbi A novel prognostic nomogram is more accurate than conventional staging systems for predicting survival after resection of hepatocellular carcinoma
    Clifford S Cho
    Hepatobiliary Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Am Coll Surg 206:281-91. 2008
    ..Numerous staging systems have been devised for purposes of risk classification; we sought to identify the optimal staging system to predict postoperative survival...
  42. ncbi A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system
    Sandra L Wong
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
    Ann Surg Oncol 12:282-8. 2005
    ..This tool takes several characteristics into account simultaneously. This model should enable improved patient counseling and treatment selection...
  43. ncbi Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum
    Thomas Steuber
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Cancer 118:1234-40. 2006
    ..Measurements of fPSA and hK2 improve on our ability to counsel patients prior to treatment as to their risk of BCR...
  44. ncbi Achieving optimal outcomes after radical prostatectomy
    Jeffery W Saranchuk
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 23:4146-51. 2005
    ..Time to full recovery is primarily dictated by recovery of erectile function. This information is helpful for patients interested in their chances of returning to their preoperative functional state...
  45. ncbi Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Clin Oncol 23:7005-12. 2005
    ..Unique to predictive models, the nomogram predictions can be adjusted for the disease-free interval that a patient has achieved after RP...
  46. ncbi Magnetic resonance imaging in the prediction of biochemical recurrence of prostate cancer after radical prostatectomy
    Michael H Fuchsjäger
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    BJU Int 104:315-20. 2009
    ..To investigate whether magnetic resonance imaging (MRI) findings, when converted into a scoring system, can predict the biochemical recurrence of prostate cancer after radical prostatectomy (RP)...
  47. ncbi Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
    Andrew J Stephenson
    Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    JAMA 291:1325-32. 2004
    ..Selected patients with high-grade disease and/or a rapid PSADT who were previously thought to be destined to develop progressive metastatic disease may achieve a durable response to salvage radiotherapy...
  48. ncbi Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk
    Kimberly Moore Dalal
    Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Ann Surg 244:381-91. 2006
    ..DSS nomograms aid in more accurate counseling of patients, identification of patients appropriate for adjuvant therapy, and stratification of patients for clinical trials and molecular analysis...
  49. ncbi A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma
    Maximiliano Sorbellini
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
    J Urol 173:48-51. 2005
    ..This nomogram may be useful for patient counseling, clinical trial design and effective patient followup strategies...
  50. ncbi Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma
    Stephen D W Beck
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg Oncol 11:71-7. 2004
    ..Knowledge of renal cortical tumor histological subtype is critical for projecting prognosis, tailoring follow-up strategies, and designing clinical trials...
  51. ncbi An updated catalog of prostate cancer predictive tools
    Shahrokh F Shariat
    Department of Urology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA
    Cancer 113:3075-99. 2008
    ..Nevertheless, many more predictive tools, comparisons between them, and improvements to existing tools are needed...
  52. ncbi Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer
    Markus Graefen
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 171:200-3. 2004
    ..CONCLUSIONS: The information provided by systematic biopsies substantially improves the ability to predict outcome following RP. However, some incremental predictive accuracy was achieved by adding systematic biopsy features...
  53. ncbi Evaluation of preoperative therapy for pancreatic cancer using a prognostic nomogram
    Rebekah R White
    Department of Surgical Oncology, Memorial Sloan-Kettering Cancer Center, New York 10021, USA
    Ann Surg Oncol 13:1485-92. 2006
    ..The ability of the nomogram to evaluate the effects of preop CRT on survival is limited by the potential effects of preop CRT on factors within the nomogram...
  54. ncbi Prognostic factors for survival in patients with hormone-refractory prostate cancer (HRPC) after initial androgen deprivation therapy (ADT)
    Daniel Cho
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
    Urol Oncol 21:282-91. 2003
    ..We believe these nomograms will become indispensable tools for patient counseling and clinical trial design in patients with HRPC...
  55. ncbi Elevated expression of caveolin is associated with prostate and breast cancer
    G Yang
    Department of Urology, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 4:1873-80. 1998
    ..Caveolin therefore appears to be associated with human prostate cancer progression and is also present in primary and metastatic human breast cancer...
  56. ncbi Potency after permanent prostate brachytherapy for localized prostate cancer
    L Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Center, NY 11570, USA
    Int J Radiat Oncol Biol Phys 50:1235-42. 2001
    ..The evaluation of potency preservation after treatment of localized prostate cancer with transperineal permanent prostate brachytherapy (PPB) and the efficacy of sildenafil were studied...
  57. ncbi Individualized prediction of colon cancer recurrence using a nomogram
    Martin R Weiser
    Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 26:380-5. 2008
    ..Although easy to implement, there remains significant heterogeneity within each stage grouping. In the era of multimodality treatment, a more refined tool is needed to predict recurrence...
  58. ncbi Nomogram for survival after primary surgery for bulky stage IIIC ovarian carcinoma
    Dennis S Chi
    Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, MRI 1026, New York, NY 10021, USA
    Gynecol Oncol 108:191-4. 2008
    ..To date, only one prediction model has been reported for patients with epithelial ovarian carcinoma (EOC). The objective of this study was to develop a more accurate survival nomogram for patients with bulky stage IIIC EOC...
  59. ncbi Predicting an optimal outcome after radical prostatectomy: the trifecta nomogram
    James A Eastham
    Division of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 179:2207-10; discussion 2210-1. 2008
    ..We evaluated our series of open radical prostatectomy cases to determine the likelihood of this outcome and develop a nomogram predicting the trifecta...
  60. ncbi The surgical learning curve for prostate cancer control after radical prostatectomy
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Natl Cancer Inst 99:1171-7. 2007
    ..We analyzed the surgical learning curve for prostate cancer recurrence after radical prostatectomy...
  61. ncbi Improved prediction of prostate cancer recurrence through systems pathology
    Carlos Cordon Cardo
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    J Clin Invest 117:1876-83. 2007
    ..This robust platform has broad applications in patient diagnosis, treatment management, and prognostication...
  62. ncbi Prostate volume measured preoperatively predicts for organ-confined disease in men with clinically localized prostate cancer
    Fernando J Bianco
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 69:343-6. 2007
    ....
  63. ncbi Preoperative nomogram predicting 12-year probability of metastatic renal cancer
    Ganesh V Raj
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    J Urol 179:2146-51; discussion 2151. 2008
    ..We developed a predictive model that could be used in the preoperative setting...
  64. ncbi Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma
    Robert J Motzer
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 113:1552-8. 2008
    ..On the basis of outcome data from that trial, the authors developed a nomogram for predicting the probability of 12-month progression-free survival for patients who received sunitinib therapy...
  65. ncbi Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy
    Brett S Carver
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    BJU Int 95:509-12. 2005
    ....
  66. ncbi Cross-cultural validation of the UCLA prostate cancer index
    Pierre I Karakiewicz
    Department of Urology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    Urology 61:302-7. 2003
    ..CONCLUSIONS: The PCI is reliable and, at best, only modestly affected by cultural differences when administered to culturally distinct English-speaking men or when translated into French...
  67. ncbi Bladder neck involvement in pathological stage pT4 radical prostatectomy specimens is not an independent prognostic factor
    Ofer Yossepowitch
    Department of Urology and Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA
    J Urol 168:2011-5. 2002
    ..Due to this and previously reported data the definition of stage pT4 disease should be modified in the next version of the TNM staging system...
  68. ncbi Race is not a predictor of prostate cancer detection on repeat prostate biopsy
    Brett S Carver
    Department of Urology, Louisiana State University Health Sciences Center and Overton Brooks Veterans Administration Medical Center, Shreveport, Louisiana, USA
    J Urol 172:1853-5. 2004
    ..We evaluated men undergoing repeat prostate biopsies for persistently increased serum prostate specific antigen (PSA) levels to determine if race was a predictor of cancer detection...
  69. ncbi Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement?
    Ilias Cagiannos
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 11021, USA
    J Clin Oncol 20:2025-30. 2002
    ..The purpose of this study was to determine whether the extent of palpable cancer within the prostate predicts outcome after radical prostatectomy...
  70. ncbi Improving the decision to pursue a phase 3 clinical trial by adjusting for patient-specific factors in evaluating phase 2 treatment efficacy data
    Glenn Heller
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Med Decis Making 27:380-6. 2007
    ..By adjusting for patient risk, this method can provide a more precise assessment of phase 2 treatment efficacy, thereby improving the decision whether to proceed to a phase 3 clinical trial...
  71. ncbi Local progression among men with conservatively treated localized prostate cancer: results from the Transatlantic Prostate Group
    James A Eastham
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Eur Urol 53:347-54. 2008
    ..Men with clinically detected localized prostate cancer treated without curative intent are at risk of complications from local tumor growth. We investigated rates of local progression and need for local therapy among such men...
  72. ncbi The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Clin Cancer Res 16:4374-81. 2010
    ..We hypothesized that the risk of prostate cancer on biopsy for a given PSA level is affected by identifiable characteristics of the cohort under study...
  73. ncbi Transition zone prostate cancer: metabolic characteristics at 1H MR spectroscopic imaging--initial results
    Kristen L Zakian
    Departments of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiology 229:241-7. 2003
    ..To determine whether cancers of the prostate transition zone (TZ) possess a unique metabolic pattern by which they may be identified at proton magnetic resonance (MR) spectroscopic imaging...
  74. ncbi Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens
    James A Eastham
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 170:2292-5. 2003
    ..We examined variations in the rate of positive surgical margins among surgeons after controlling for the severity of disease and volume of cases per surgeon...
  75. ncbi Prediction of seminal vesicle invasion in prostate cancer: incremental value of adding endorectal MR imaging to the Kattan nomogram
    Liang Wang
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 242:182-8. 2007
    ..To retrospectively determine whether endorectal magnetic resonance (MR) imaging findings contribute incremental value to the Kattan nomogram for predicting seminal vesicle invasion (SVI) in patients with prostate cancer...
  76. ncbi A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy
    Kimberly J Van Zee
    Departments of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA
    Ann Surg Oncol 10:1140-51. 2003
    ..Accurate estimates of the likelihood of additional disease in the axilla could assist greatly in decision-making regarding further treatment...
  77. ncbi Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer
    Michael J Zelefsky
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Urology 70:283-7. 2007
    ....
  78. ncbi Variations in lung cancer risk among smokers
    Peter B Bach
    The Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Natl Cancer Inst 95:470-8. 2003
    ..We sought to determine whether the risk of lung cancer varies predictably among smokers...
  79. ncbi Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach
    Andrew J Vickers
    Department of Epidemiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 115:5460-9. 2009
    ....
  80. ncbi Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Eur Urol 53:960-6. 2008
    ..We previously demonstrated that there is a learning curve for open radical prostatectomy. We sought to determine whether the effects of the learning curve are modified by pathologic stage...
  81. ncbi Systematic review of statistical methods used in molecular marker studies in cancer
    Andrew J Vickers
    Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York City, New York 10021, USA
    Cancer 112:1862-8. 2008
    ..In the current study, the experimental designs and statistical methods used in contemporary molecular marker studies are reviewed, particularly with respect to whether these evaluated a marker's clinical value...
  82. ncbi A comprehensive and novel predictive modeling technique using detailed pathology factors in men with localized prostate carcinoma
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York 11570, USA
    Cancer 95:1451-6. 2002
    ....
  83. ncbi Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Urol 172:1286-90. 2004
    ..We prospectively evaluated RC cases with transitional cell carcinoma of the bladder to determine which factors may contribute to the variability in the number of reported LNs...
  84. ncbi Variations in morbidity after radical prostatectomy
    Colin B Begg
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York 10021, USA
    N Engl J Med 346:1138-44. 2002
    ..Recent studies of surgery for cancer have demonstrated variations in outcomes among hospitals and among surgeons. We sought to examine variations in morbidity after radical prostatectomy for prostate cancer...
  85. ncbi Against diagnosis
    Andrew J Vickers
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Intern Med 149:200-3. 2008
    ..The authors compare and contrast the diagnostic and risk prediction approaches and attempt to identify the types of medical problem to which each is best suited...
  86. ncbi Clinical stage T1c prostate cancer: pathologic outcomes following radical prostatectomy in black and white men
    James A Eastham
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Prostate 50:236-40. 2002
    ....
  87. ncbi The prognostic significance of Gleason Grade in patients treated with permanent prostate brachytherapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Int J Radiat Oncol Biol Phys 56:749-54. 2003
    ..To assess the difference in biochemical freedom from relapse (BFR) between patients with clinically localized prostate cancer having Gleason Grade (GG) 3 + 4 vs. 4 + 3 disease treated with permanent prostate brachytherapy (PPB)...
  88. ncbi Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group
    Howard I Scher
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    J Clin Oncol 22:537-56. 2004
    ..To define methodology to show clinical benefit for patients in the state of a rising prostate-specific antigen (PSA)...
  89. ncbi Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition
    Andrew J Stephenson
    Department of Urology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 24:3973-8. 2006
    ..Ten definitions of BCR were evaluated to identify the one that best explains metastatic progression...
  90. ncbi Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging
    Michael Mullerad
    Department of Urology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiology 232:140-6. 2004
    ..To determine whether predictive value of endorectal magnetic resonance (MR) imaging findings in detection of prostate cancer extracapsular extension (ECE) is significantly affected by the reader's subspecialty experience...
  91. ncbi The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy
    Hedvig Hricak
    Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 100:2655-63. 2004
    ..In the current study, the authors determined the incremental value of endorectal magnetic resonance imaging (eMRI) in making this decision...
  92. ncbi Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival
    Cristina R Ferrone
    Memorial Sloan Kettering Cancer Center, Department of Surgery, 1275 York Ave, Box 435, New York, NY 10021, USA
    J Clin Oncol 23:7529-35. 2005
    ..A single US institution database was used to test the validity of the pancreatic adenocarcinoma nomogram established at Memorial Sloan-Kettering Cancer Center...
  93. ncbi External radiotherapy and permanent prostate brachytherapy in patients with localized prostate cancer
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Brachytherapy 1:36-41. 2002
    ..Cox regression failed to identify an improvement in PSA-FFR with RT-PPB or the addition of hormones. Although these conclusions question the role for RT-PPB, only a comparative trial will be able to answer this question definitively...
  94. ncbi Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas
    Murray F Brennan
    Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Ann Surg 240:293-8. 2004
    ..Predictive nomograms are becoming increasingly used to define and predict outcome. They can be developed at presentation or following treatment and include variables not conventionally used in standard staging systems...
  95. ncbi Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension
    Liang Wang
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Radiology 232:133-9. 2004
    ..To assess the incremental value of endorectal magnetic resonance (MR) imaging findings in addition to clinical variables for prediction of extracapsular extension (ECE) in patients with prostate cancer...
  96. ncbi Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms
    Liang Wang
    Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 238:597-603. 2006
    ..To assess retrospectively the incremental value of endorectal coil magnetic resonance (MR) imaging and combined endorectal MR imaging-MR spectroscopic imaging to the staging nomograms for predicting organ-confined prostate cancer (OCPC)...
  97. ncbi Primer: using decision analysis to improve clinical decision making in urology
    Elena B Elkin
    Health Outcomes Research Group, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nat Clin Pract Urol 3:439-48. 2006
    ..Greater incorporation of decision-analytic techniques into urology research and clinical practice might improve decision making, and thereby improve patient outcomes...
  98. ncbi The effect of isotope selection on the prostate-specific antigen response in patients treated with permanent prostate brachytherapy
    Louis Potters
    Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, NY 11570, USA
    Brachytherapy 2:26-31. 2003
    ..To assess the difference in prostate-specific antigen (PSA) response kinetics in patients undergoing either (125)I or (103)Pd permanent prostate brachytherapy (PPB)...
  99. ncbi Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy
    Kristen L Zakian
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    Radiology 234:804-14. 2005
    ..To determine whether hydrogen 1 magnetic resonance (MR) spectroscopic imaging can be used to predict aggressiveness of prostate cancer...
  100. ncbi Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer
    Bernard H Bochner
    Department of Urology, Memorial Sloan Kettering Cancer Center, Kimmel Center for Prostate and Urologic Tumors, 353 E 68th St, New York, NY 10021, USA
    J Clin Oncol 24:3967-72. 2006
    ..The goal of this study was the development of a prognostic outcomes nomogram to predict the 5-year disease recurrence risk after radical cystectomy...
  101. ncbi Benchmarking lung cancer mortality rates in current and former smokers
    Peter B Bach
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, Box 221, New York, NY 10021, USA
    Chest 126:1742-9. 2004
    ..The model is intended for use in analyzing a population of subjects who are undergoing lung cancer screening or receiving lung cancer chemoprevention, to determine whether the intervention has altered lung cancer mortality...